A comparison of antidepressant trials using active and inert placebos

International Journal of Methods in Psychiatric Research

Volumn 12, Issue 3, 2003, Pages 117-127

  Moncrieff, Joanna ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antidepressants; Double blind; Meta analysis; Placebo

Indexed keywords

ANTIDEPRESSANT AGENT; IMIPRAMINE; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; HOSPITAL PATIENT; HUMAN; INTERMETHOD COMPARISON; MEDLINE; META ANALYSIS; METHODOLOGY; OUTPATIENT CARE; PREDICTION; QUALITY CONTROL; REGRESSION ANALYSIS; REVIEW; SAMPLE SIZE; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; HUMANS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS;

EID: 0141605973     PISSN: 10498931     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpr.148     Document Type: Review

References (55)

1. Abraham HC, Kanter VB, Rosen I, Standen JL. A controlled clinical trial of imipramine with out-patients. British Journal of Psychiatry 1963; 109: 286-93.
2. Ainslie, JD, Jones MB, and Stiefel JR. Practical drug evaluation method. Archives of General Psychiatry 1965; 12: 368-73.
3. Anderson IM, Nutt DJ, Deakin JFW on behalf of the Consensus Meeting and endorsed by the British Association of Psychopharmacology. Evidence based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology Guidelines. Journal of Psychopharmacology 2000; 14: 3-20.
4. Angst J, Scheidegger P, Stabl M. Efficacy of moclobemide in different patient groups: results of new subscales of the Hamilton Rating, Scale. Clinical Neuropharmacoloigy 1993; 16 (Suppl. 2): S55-S62.
5. Bellack AS, Hersen M, Himmellhoch J. Social skills training compared with pharmacotherapy and psychotherapy in the treatment of unipolar depression. American Journal of Psychiatry 1981; 138: 1562-7.
6. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. British Journal of Psychiatry 1999; 174: 297-303.
7. Brick H, Doub WHJ, Perdue WC. Effects of amitriptylene on depressive and anxiety states in penitentiary inmates. Diseases of the Nervous System 1962; 22: 572-8.
8. Daneman EA. Imipramine in office management of depressive reactions. Diseases of the Nervous System 1961; 22: 213-17.
9. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In M Egger, GD Smith, DG Altman (eds) Systematic Reviews in Health Care, second edition. London: BMJ Publishing Group, 2001.
10. Diamond S. Double-blind controlled study of amitriptylene-perphenazine combination in medical office patients with depression and anxiety. Psychosomatics 1966; 7: 371-5.
11. Elkin I, Shea T, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PA, Leber WR, Docherty JP, Fiester SJ, Parloff MB National Institute of Mental Health treatment of depression collaborative research program. Archives of General Psychiatry 1989; 46: 971-82.
12. Engelhardt DM, Margolis RA, Rudorfer L, Paley HM, Physician bias and the double-blind. Archives of General Psychiatry 1969; 20: 315-20.
13. Even C, Siobud-Dorocant, Dardennes Critical approach to antidepressant trials. Blindness protection is necessary, feasible and measurable. British Journal of Psychiatry 2000; 177: 47-51.
14. Fink M, Klein DF, Kramer JC. Clinical efficacy of chlorpromazine-procyclidine combination, imipramine and placebo in depressive disorders. Psychopharmacologia 1965; 7: 27-36.
15. Friedman AS, Granick S, Cohen HW, Cowitz B. Imipramine (tofranil) vs placebo in hospitalized psychotic depressives. Journal of Psychiatric Research 1966; 4: 13-36.
16. Friedman AS. Interaction of drug therapy with marital therapy in depressive patients. Archives of General Psychiatry 1975; 32: 619-37.
17. Garry JW, Leonard TJ. Trial of amitriptylene in chronic depression. British Journal of Psychiatry 1963; 109: 54-5.
18. Greenberg RP, Fisher S. Suspended judgement. Seeing through the double masked design: a commentary. Controlled Clinical Trials 1994; 15: 244-6.
19. Hall J, Louie D. A controlled trial of amitriptylene for treatment of depression in inpatients. New Zealand Medical Journal 1962; 61: 548-50.
20. Hamilton MA. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960; 23: 56-62.
21. Hazell P, O'Connell D, Heathcote D, Robertson J, Henry D. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ 1995; 310: 897-901.
22. Holdway V. Trial of imipramine. Journal of Mental Science 1960; 106: 1443-6.
23. Hollister LE, Overall JE, Johnson M, Katz G, Kimbell I, Honigfeld G. Evaluation of desipramine in depressive states. Journal of New Drugs 1963; 3: 161-6.
24. Hollister LE, Overall JE, Johnson M, Pennington V, Katz G, Shelton J. Controlled comparison of imipramine, amitriptyline and placebo in hospitalised depressed patients. Journal of Nervous and Mental Disease 1964; 139: 370-5.
25. Hussain Z. Drugs in depressive illness. British Medical Journal 1970; 1: 482
26. Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. Journal of Clinical Psychopharmacology 2002; 22: 40-5.
27. Kirsch I The emperor's new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prevention and Treatment, 2002; 5, available at http://journals.apa.org/prevention
28. Kocsis JH, Croughan JL, Katz MM, Butler TP, Secunda C, Bowden CL, Davis JM. Response to treatment with antidepressants of patients with severe or moderate non psychotic depression and of patients with psychotic depression. Am J Psychiatry 1990; 147: 621-4.
29. Kranzler HR, Burleson JA, Korner P, Del Boca FK, Bohn MJ, Brown J, Liebowitz N. Placebo controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995; 152: 391-7.
30. Lorr M, Jenkins R, Holsopple J. Multidimensional scale for rating psychiatric patients. Veterans Administration Technical Bulletin. Washington: Veterans Association, 1953; 10-507.
31. Master RS. Amitriptyline in depressive states. A controlled trial in India. British Journal of Psychiatry 1963; 109: 826-9.
32. McCallum P, Reares R. A controlled trial of mapriotiline in depressed out-patients. Medical Journal of Australia 1975; 2: 392-3.
33. Moncrieff J, Churchill R, Drummond DC, McGuire H. Development of a quality assessment instrument for trials of treatments of depression and neurosis. International Journal of Methods in Psychiatric Research 2001b; 10: 126-33.
34. Moncrieff J, Wessely S, Hardy R. Meta-analysis of trials comparing antidepressants with active placebos. British Journal of Psychiatry 1998; 172: 227-31.
35. Moncrieff J, Wessely S, Hardy R. Antidepressants versus active placebos. Cochrane Database of Systematic Reviews, 2001a.
36. Morris JB, Beck AT. The efficacy of antidepressant drugs. A review of research (1958 to 1972). Archives of General Psychiatry 1974; 30: 667-74.
37. Murphy GE, Simons AD, Wetzel RD, Lustman PJ. Cognitive therapy and pharmacotherapy. Archives of General Psychiatry 1984; 41: 33-41.
38. Ottervanger EA The efficacy of fluvoxamine in patients with severe depression. British Journal of Clinical Research 1991; 2: 125-32.
39. Overall JE. Dimensions of manifest depression. Journal of Psychiatric Research, 1962; 1: 239-248.
40. Paykell ES Hollyman JA, Freeling P, Sedgwick P. Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo controlled trial. Journal of Affective Disorders 1988; 14: 83-95.
41. Porter AMW. Depressive illness in a general practice. A demographic study and a controlled trial of imipramine. BMJ 1970; 1: 773-8.
42. Prange AJ, McCurdy RL, Cochrane CM. The systolic blood pressure response of depressed patients to infused norepinephrine. Journal of Psychiatric Research 1967; 5: 1-13.
43. Quality Assurance Project. A treatment outline for depressive disorders. Australian and New Zealand Journal of Psychiatry 1983; 17: 129-46.
44. Quitkin FM, Rabkin JG, Gerald J, Davis JM, Klein DF. Validity of clinical trials of antidepressants. American Journal of Psychiatry 2000; 157: 327-37.
45. Raskin A, Crook TH. Antidepressants in black and white inpatients. Archives of General Psychiatry 1975; 32: 643-9.
46. Raskin A, Schulterbrandt JG, Reatig N, Chase C, McKeon JJ. Differential response to chlorpromazine, imipramine and placebo. Archives of General Psychiatry 1970; 23: 164-73.
47. Rickels K, Ward CH, Schut L. Different populations, different responses. A comparative study of two antidepressants each used in two different patient groups. American Journal of Medical Science 1964; 47: 328-35.
48. Smith RC. Amoxapine, imipramine and placebo in depressive illness. Current Therapeutic Research 1975; 18: 346-53.
49. Stata 7. Texas, USA: Stata Corporation, 2002.
50. Thompson S. Why and how sources of heterogeneity should be investigated. In M Egger, GD Smith, DG Altman (eds) Systematic Reviews in Healthcare. London: BMJ Publishing Group, 2001.
51. Toneatto T, Setlers EM. Perception of whether drug or placebo has been administered is a determinant of drinking reduction. In EM Sellers and CA Naranjo (eds) Novel Pharmacological Interventions for Alcoholism. California: Springer Verlag 1992.
52. Uhlenhuth EH, Park LC. The influence of medication (imipramine) and doctor in relieving depressed psychoneurotic outpatients. Journal of Psychiatric research 1963; 2: 101-22.
53. Weintraub W, Aronson H. clinical judgment in psychopharmacological research. Journal of Neuropsychiatry 1963; 5: 65-70.
54. White K, Kando J, Park T, Waternaux C, Brown WA. Side effects and the 'blindability' of clinical drug trials. American Journal of Psychiatry 1992; 149: 1730-61.
55. Wilson IC, Vernon JT, Guin T, Sandifer MG. A controlled study of treatments of depression. Journal of Neuropsychiatry 1963; 4: 331-7.